Connect with us

INDUSTRIAL HEMP

Cannabis Science Inc (OTCMKTS:CBIS) Releases Update On Cannabinoid Drug Candidate To Treat ACOS

Published

on

Cannabis Science Inc (OTCMKTS:CBIS) reported that its research staff is approaching completion of a unique new cannabinoid formulary to cure the Chronic Obstructive Pulmonary Disease and Asthma Overlap Syndrome with clinical studies to follow upon completion.

The details

Dr. Allen Herman, the Chief Medical Officer of Cannabis Science, reported that their recent advancement of their MDI and Rescue Inhaler drugs for these subjects in part is the reason the respective research evolved to cure this under-diagnosed syndrome. While their formulations for these drugs achieve the desired outcomes for the illness intended as a rescue drug they cannot cure effectively the diagnosis of the ACOS. More interesting is the occurrence of ACOS noted among populations of people diagnosed with COPD.

Herman added that Cannabis Science new formulary will target four distinct aspects of this ailment, airway constriction, inflammation, anxiety and capacity. Cannabinoid extracts have several unique properties and as an inflammatory agent, these extracts even help in controlling anxiety.

The strain they are working with marks as the one that showcases lung expansion properties. This specific strain chemical makeup leads the lungs to hyper-inflate or expand once the dose has been given and over a contributed to therapy term is projected to build back the strength of lung muscle in the weakened lungs together with increased volume capacity.

This is a remarkable market division, with around 5 million people with known cases of COPD in the U.S. alone and the 20% occurrence of the ACOS provides a known market of around five million doses a month potential for Cannabis Science new formula.

Raymond C. Dabney, the CEO and President of Cannabis Science, reported that they are looking to offer long-term therapy as well as short-term relief addressing the Asthma part of the syndrome. They will offer the required support for the COPD part targeting panic, inflammation, constriction and anxiety.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement